A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

Inclusion Criteria Concurrent Medication: Allowed: * Methadone maintenance. Therapies available through expanded access or treatment IND programs unless specifically excluded. * Allowed within 30 days of study entry: * Systemic steroids only if given for treatment of Pneumocystis carinii pneumonia. * Recommended: * PCP prophylaxis. Patient must have: * Recovered from first episode of histologically proven Pneumocystis carinii pneumonia (PCP) or microbiologically proven AIDS-defining opportunistic infection as defined in Centers for Disease Control HIV classification group IV. * C-1. * Study entry must be within 120 days of AIDS-defining diagnosis. * Written documentation of positive antibody to HIV by any federally licensed ELISA test kit. This test should be confirmed by another method, for example, Western blot, radioimmunoassay (RIA), HIV culture. * Patients cannot be transfusion dependent (requiring blood transfusion more than once per month). The last transfusion must be \> 2 weeks before entry. * AMENDED 90-08-27 to include HIV positive patients with CD4+ count \< 200 cells/mm3. Prior Medication: Allowed: * Zidovudine (AZT) for \< 365 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Symptomatic visceral or progressive Kaposi's sarcoma (KS) (defined by \> 10 new lesions in the 30 days prior to entry). * Other concurrent neoplasms other than basal cell carcinoma of skin (patients who have been in …